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ABSTRACT 
Purpose of review. This review summarises the main challenges of antimicrobial resistance (AMR) in 
the neonatal population with a special focus on multidrug-resistant (MDR) Gram-negative (GN) 
pathogens.   
Recent findings. MDR-GN bacteria are a great concern in the neonatal population, with a worldwide 
rise in the reported incidence and with very limited therapeutic options. Extended-Spectrum β-
Lactamase (ESBL) and Carbapenem-Resistant Enterobacteriaceae (CRE) have been reported as 
responsible for NICU outbreaks. Hospital data from low/middle-income countries show high 
proportions of isolates from neonates resistant to the WHO first-line and second-line recommended 
treatments. The spread of CRE has resulted in old antibiotics, such as colistin and fosfomycin, to be 
considered as alternative treatment options, despite the paucity of available data on safety and 
appropriate dosage. 
Summary. Improved global neonatal AMR surveillance programmes including both epidemiology 
and clinical outcomes are critical for defining the burden and designing interventions. The optimal 
empiric treatment for neonatal sepsis in settings of high rates of AMR is currently unknown. Both 
strategic trials of older antibiotics and regulatory trials of new antibiotics are required to improve 
clinical outcomes in MDR-GN neonatal sepsis.  
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INTRODUCTION  
Maternal and child deaths have halved worldwide over the past two decades [1]. However, neonatal 
mortality has remained unacceptably high, with an estimated 2.9 million deaths in newborns within 
the first 28 days of life every year. Among them, nearly a quarter is directly due to infectious causes 
(23%), with neonatal sepsis accounting for 15% [1]. Severe bacterial infections (SBI) in neonates 
account for about 3% of all disability-adjusted life years (DALY) [2]. Infection-attributable deaths, 
together with survivors of severe sepsis in the neonatal period, contribute largely to the global 
burden of disease. 
Appropriate empirical treatment of SBI is crucially important in reducing mortality. However, it 
requires knowledge of the relative proportions of causative organisms at a local level as well as their 
resistance patterns collected using standardised methods. Multidrug-resistant (MDR) pathogens are 
now a challenge in both high-income (HIC) and low/middle-income countries (LMIC) [3]. Neonates 
admitted to Neonatal Intensive Care Units (NICU), especially premature infants, have been identified 
to be at high-risk for the selection and transmission of MDR pathogens. Recently, the first estimate 
of neonatal deaths attributable to resistant sepsis has been published, with antimicrobial resistance 
(AMR) potentially responsible for around 30% of all global neonatal sepsis deaths [4**]. 
This review summarises the main challenges of AMR in the neonatal population with a special focus 
on MDR Gram-negative (GN) pathogens.   
 
GLOBAL EPIDEMIOLOGY AND CLINICAL IMPACT OF AMR IN NEONATES  
Historically, the main resistant pathogens encountered in the hospital setting were Gram-positive 
bacteria. Among them, methicillin-resistant Staphylococcus aureus (MRSA) was a critically important 
pathogen in the NICU population, being associated with both endemic and epidemic infections [5]. 
4 
 
Enterococci spp. are less-frequent, however, ampicillin-resistant and, more recently, vancomycin-
resistant enterococci have been described in NICUs [6*]. 
Currently, it is MDR Gram-negative bacteria that are the greatest concern in the neonatal 
population, with a worldwide rise in the reported incidence and with very limited therapeutic 
options [7]. AMR among the Enterobacteriaceae represents a major problem in both healthcare-
associated and community-acquired neonatal infections. 
 
Extended-Spectrum β-Lactamase (ESBL)–Producing Enterobacteriaceae  
The ESBLs are the result of a single nucleotide polymorphism in the blaSHV gene producing a family 
of enzymes able to hydrolyse the β-lactam ring [8]. There are many phenotypic and genetic 
differences among β-lactamases, with a common result that β-lactam antibiotics, such as penicillins, 
cephalosporins, and monobactams, are inactivated, leading to ineffective therapy. ESBLs are 
inhibited by β-lactam inhibitors (clavulanic acid, tazobactam, and sulbactam) [9]. β-lactamase genes 
are mostly carried on mobile genetic elements, frequently harbouring other resistance genes 
conferring resistance to other antibiotic classes [10]. The most common ESBLs are members of the 
SHV, TEM, and CTX-M (Ambler Class A) families (Table 1) [9].  
Recently, many studies have been conducted globally on the prevalence of both community- and 
hospital-acquired ESBL-infections in neonates. ESBL-producing Enterobacteriaceae have been 
responsible for an increasing number of NICU outbreaks [11-15*].  
Data from HIC showed a consistent rise in the rate of ESBL-positive isolates among neonatal units. A 
two-centre case–control study of children aged 0-17 years conducted in the US showed that 11/30 
ESBL-producing isolates were in babies on NICU [10]. European data from the ARPEC study reported 
rates of resistance to 3rd-generation cephalosporins between 6.6 and 39.5% among 
Enterobacteriaceae in children less than 1 year [16]. A study conducted in Taiwan on 393 cases of GN 
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bacteraemia in NICU patients showed that the most frequent mechanism of resistance was ESBL-
production that accounted for 67.1% of MDR strains [17]. MDR-GN bacteraemia was associated with 
a poorer outcome, with significantly higher rates of complications and overall case fatality. Another 
case-control analysis conducted in Taiwan between 2001 and 2012 reported that 14.2% of all 
neonatal GN late-onset sepsis were due to ESBL-producing strains (62.3% of Klebsiella spp, 20.8% of 
Echerichia coli, and 16.9% of Enterobacter spp). The SHV-type ESBLs were the most prevalent among 
these patients (67% of ESBLs), with most strains being genetically unrelated. In this study, neonates 
infected with ESBL-GN strains had higher rates of infectious complications (p = 0.008) and adverse 
outcomes (p=0.049) compared to non-ESBLs [18]. 
Although ESBL-producing Enterobacteriaceae are of global concern, they represent an even greater 
burden in LMIC. Asian studies showed a global rise in rates of ESBLs among hospitalised neonates. 
Data from a recent Indian study showed that 87% of E. coli isolated from septic neonates were ESBL-
producers. CTX-M-15 was the most commonly identified ESBL (81%), reflecting its global 
dissemination [14]. The rates of β-lactamase production reported in 103 neonates in a referral 
hospital in Iran was 95.5% among Klebsiella pneumoniae and 78.6% among E. coli isolates. Infections 
caused by ESBL-producing pathogens were associated with longer hospital stay [13].  
The same trend was highlighted in studies from South America, where an overall rate of 73.3% of 
ESBL-producers was identified in Peru among neonates infected with K. pneumoniae, with CTX-M-15 
and CTX-M-2 the most commonly detected ESBLs [19]. Another study in Venezuela described the 
first nosocomial outbreak of ESBL-producing Enterobacter ludwigiian in neonates [12].  
ESBL outbreaks in NICUs have been associated with suboptimal hygiene standards, with 
understaffing reported as a major risk factor [15*]. In non-outbreak settings, variables 
independently associated with ESBL infections in neonates included prematurity, low birth weight, 
prolonged hospitalization, invasive devices, and previous antibiotic use [8].    
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Carbapenem-Resistant Enterobacteriaceae (CRE) 
The use of carbapenems has increased worldwide during the last decade due to the spread of ESBL-
producing pathogens. Carbapenemases genes have been recently identified on mobile genetic 
elements, therefore favouring both person-to-person and species-to-species spread. Dynamics of 
spread and associated-resistance phenotypes vary according to different resistance determinants 
[20**]. Molecular classification of carbapenemases includes Ambler class A, B, and D, distinguished 
by the site of the hydrolytic mechanism (Table 1) [21].  
Various studies have been published recently on the geographical expansion of CRE worldwide. After 
the global dissemination of K. pneumoniae carbapenemase (KPC)-producers, OXA-48 and New Delhi 
metallo-β-lactamase (NDM)-positive strains are now increasingly being reported [22]. However, 
limited data have been published on the epidemiology of CRE infections in the neonatal population, 
and the available data is largely limited to case reports or small case series. Nosocomial outbreaks 
have been reported in NICUs, and the geographic distribution is broadly comparable with data 
reported in adults [23]. It is unclear at present whether ESBL and CRE prevalence on neonatal units 
broadly reflects national resistance patterns or neonatal unit specific resistance profiles. 
The majority of reports on the dissemination of CRE among the neonatal population in the last years 
has been published from South-East Asia and Western Pacific Regions. An outbreak of NDM-1-
producing K. pneumoniae was recently reported in the neonatal ward of a teaching hospital in 
mainland China [24]. The isolates were shown to be clonally related and harboured a sequence type 
17. The first blaNDM-1-positive K. pneumoniae in China was isolated in 2012. Since then, a number 
of reports have been published showing a continuous spread of blaNDM-1. In other areas of NDM 
endemicity, such as India, NDM-1 has been the predominant carbapenemase among neonates. In a 
5-year study on neonatal sepsis in a tertiary care NICU in Kolkata, India, NDM-1 was identified in 14% 
of the 105 isolates, and was the only carbapenemase detected [25]. The same trend in the same 
hospital was highlighted in another 7-year study on carbapenem-resistant Acinetobacter baumannii 
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causing neonatal sepsis. Again, blaNDM−1 was the major contributor to carbapenem-resistance [26]. 
Another K. pneumoniae sepsis outbreak described in a NICU in central India reported that all the 
isolates were positive for blaNDM-1 with co-association of blaCTX-M-15 [27]. The first study using 
whole-genome sequencing to characterise an extended outbreak caused by carbapenem-resistant K. 
pneumoniae in a neonatal unit in Nepal revealed that the case clusters were all caused by a single 
NDM K. pneumoniae with a conserved set of four plasmids, one carrying blaNDM-1 gene [28]. In this 
study, the mortality rate among infected neonates was 64% (16/25). 
Relatively few data has been published on the epidemiology of neonatal CRE in the African region, 
mainly from the North African countries. A large study conducted on 1,287 newborns in Morocco 
showed that 34 out of 157 isolated Enterobacteriaceae were carbapenemase-producing, with OXA-
48 the predominant type [29].  However, no statistically significant difference in mortality was 
shown between neonates infected with CRE and non carbapenem-resistant strains.  
Data from neonatal units in Europe and the US generally reflect the distribution of CRE in adults. A 
recent study published in Italy on a national cohort of 69 children infected or colonised with CRE 
confirmed the endemic role of the KPC carbapenemase in Southern Europe and the Mediterranean 
region, with 61.4% of CRE being KPC-producing and 13.6% harbouring the OXA-48 type [30].  
 
Plasmid-mediated Colistin-Resistant Enterobacteriaceae 
With the global increase in the prevalence of CRE, polymyxins have become a last-resort treatment 
option, with an increase in the human consumption of colistin and an inevitable risk of emerging 
resistance. Recently, the emergence of plasmid-mediated mcr-1 gene conferring colistin-resistance 
has become a great challenge to public health [31]. This gene has been identified firstly in animals 
and humans in China, but is now being reported in several other countries [32]. New agents effective 
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against MDR-GN pathogens are lacking, and the impact of mobile colistin resistance genes on global 
health cannot be underestimated.  
The first report published in 2016 on the detection of mcr-1 gene in K. pneumoniae and E. coli 
isolated from an infant with diarrhoea in China raised huge concerns [33**]. Due to the very limited 
therapeutic options, the emergence of mcr-1-positive isolates in neonates represents an enormous 
challenge. Furthermore, the simultaneous isolation of this gene in two different pathogens from the 
same patient is likely to suggest horizontal transmission.  
 
CHALLENGES IN AVAILABLE TREATMENTS 
Hospital data from LMIC reported in a recent systematic review shows that nearly half of pathogens 
causing SBI in neonates are resistant to the WHO first-line recommended regimen of ampicillin (or 
penicillin) and gentamicin, and to the second-line treatment with 3rd-generation cephalosporins 
[4**, 34-36]. These findings could potentially have significant implications for global antibiotic 
recommendations in neonatal settings [37-38*-39]. The current WHO’s Pocketbook of Hospital Care 
for Children provides the same empiric guidance for probable SBI in both early-onset and late-onset 
sepsis in both the community and hospital setting. However, the risks of MDR-GN sepsis may vary 
considerably between early-onset in the rural population and late-onset nosocomial infections in 
large neonatal units.   
Babies are particularly at risk for adverse outcomes from sepsis due to MDR-Enterobacteriaceae, 
with few available effective antimicrobials approved for neonatal use and the pipeline for novel 
antibiotics in advanced development limited (Table 2).  
The role of β-lactam–β-lactamase inhibitors (BL/BLIs) for the treatment of ESBL infections is still 
controversial since many organisms have been shown to produce multiple ESBLs simultaneously, 
therefore reducing the effectiveness of the inhibitor. The available literature is limited to 
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observational studies where BL/BLIs have been compared with carbapenems in neonates with ESBL-
producing Enterobacteriaceae, showing no difference in clinical outcomes [42]. Carbapenems have 
become the treatment of choice for neonatal ESBL-infections, and should be used as monotherapy 
since no evidence of benefit from addition of an aminoglycoside has been demonstrated [40].  
The optimal treatment for CRE infections in adults has not been defined yet due to the lack of large 
randomised studies evaluating different therapeutic approaches. Small case series seem to support 
the use of combination therapy to significantly reduce mortality [22].  
The emergence and spread of CRE among NICU patients has led to old antibiotics, such as colistin 
and fosfomycin, to be reconsidered, even if the increasing prevalence of colistin-resistant CRE is of 
high concern [32, 33**, 43]. 
Colistin is increasingly used in the neonatal population. However, few studies have been published 
about its use in neonatal sepsis, and none of them focussed specifically on infections caused by CRE. 
Colistin is associated with renal toxicity, with significant rates of acute kidney injury reported in 
adults [20**]. In a retrospective study on 12 neonates infected with MDR-GN bacteria, the 
intravenous treatment with colistin seemed to be safe and efficacious, including for preterm babies 
[44]. Another retrospective study on 21 neonates treated with colistin for MDR Acinetobacter sepsis 
showed a surviving rate of 91%, with no renal impairment being documented [45]. A similar report 
on preterm neonates with nosocomial sepsis caused by A. baumannii showed a recovery rate of 81% 
in babies receiving IV colistin, with acute kidney injury reported in 19% [46]. A recent PK study on 7 
critically ill neonates with GN infections highlighted that a single IV dose of colistin at the currently 
recommended dosage resulted in suboptimal plasma concentrations [47].  
There is little experience of using fosfomycin in neonates, and it should be considered as a final-
resort option for extensively-drug resistant GN [48]. This drug has a broad-spectrum of bactericidal 
activity and is active against the majority of CRE isolates, with the advantage that it achieves 
excellent concentrations in urine, plasma, bronchoalveolar and cerebrospinal fluid, with low rates of 
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toxicity [40]. Resistance to fosfomycin can develop rapidly if used as monotherapy, but if combined 
with other agents the chance of developing resistance is limited [42].  
Tigecycline is active against many difficult-to-treat MDR-GN. However, due to the possible effects on 
bone growth, the use in neonates could only be justified when other effective antibiotics are not 
available [40, 42, 48].  
At the moment, 37 new antibiotics are listed on the Pew Charitable Trusts Antibiotic Pipeline, with 
few of them, such as aztreonam-avibactam, carbavance (vaborbactam+meropenem) and plazomicin, 
specifically targeting infections caused by CRE [49]. However, there is only one study currently 
ongoing on the safety and pharmacokinetics of carbavance in children that includes neonates [50].  
  
CONCLUSIONS AND FUTURE PERSPECTIVES  
Standardised global surveillance programmes collecting neonatal AMR data including risk factors and 
clinical outcomes are critical to allow benchmarking and design interventions. Studies published so 
far reported conflicting data about the relationship between currently-defined MDR isolates and 
neonatal mortality. This should be addressed properly through prospective studies focussing on 
clinical impact of AMR in neonatal sepsis. 
It should be noted that although the increasing emphasis on in-hospital births in LMIC may led to 
improve neonatal outcomes in terms of birth complications and stillbirths, this may be at the 
expense of increased exposure of babies to highly-resistant hospital flora, and to the subsequent 
spread of AMR. 
The impact of different risk factors at both baby- and hospital-level is still debated. Due to the 
paucity and high heterogeneity of available studies, firm conclusions on the correlation between 
GNB colonisation and BSI in neonates cannot be made at the moment, with the few existing data too 
weak to be used for clinical decision-making.  
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The optimum choice of drug, dose, and duration to treat neonatal sepsis in settings of high 
resistance to WHO first-line empirical therapy is still unknown. The evidence-base for the use of new 
(and older) antibiotics needs to be developed through both strategic and regulatory clinical trials in 
order to define the best available treatment and improve the management of these severe 
infections in neonates, especially in LMIC setting. Harmonisation of surveillance definitions, including 
age groups and outcome measures, would also allow pooling data from different datasets.  
 
Key points: 
• ESBL-producing and Carbapenem-resistant Enterobacteriaceae are of great concern in the 
neonatal population, with a worldwide rise in the reported incidence and with very limited 
therapeutic options. 
• Alarming proportions of pathogens causing SBI in neonates are now reported to be resistant 
to the WHO first-line and second-line recommended treatments. 
• The spread of CRE among NICU patients has resulted in the increasing use of old antibiotics 
in neonates, despite the paucity of available data on safety and appropriate dosage. 
• The evidence-base for the use of new (and older) antibiotics needs to be developed through 
both strategic and regulatory clinical trials in order to define the best available treatment for MDR-
GN infections in neonates. 
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Table 1: Summary of resistance mechanisms and phenotypes for clinically important β-lactamases 
according to Ambler classification 
Ambler 
classification 
Resistance 
mechanism 
Representative 
enzymes 
Genetic basis Relevant organisms Substrates 
Class A 
ESBLs TEM, SHV, CTX-M Plasmid 
Escherichia coli, Klebsiella spp, 
Proteus mirabilis 
Penicillins,  
3rd gen-cephalosporins 
Carbapenemases KPC Plasmid 
Klebsiella pneumoniae, E. coli, 
Klebsiella oxytoca, Serratia 
marcescens, Enterobacter spp, 
Citrobacter freundii 
All β-lactams 
Class B 
Carbapenemases, 
metallo-β-lactamases 
VIM, IMP, NDM-1 Plasmid 
K. pneumoniae, E. coli, K. 
oxytoca, S. marcescens, 
Enterobacter spp, C. freundii 
All β-lactams, except 
monobactams 
Class C Cephalosporinases AmpC Chromosomal 
K. pneumoniae, E. coli, 
Enterobacter spp, Salmonella 
enteritidis, C. freundii, S. 
marcescens 
Cephamycins,  
3rd gen-cephalosporins 
Class D Carbapenemases OXA Plasmid 
Acinetobacter baumannii, 
Pseudomonas aeruginosa, E. Coli, 
K. Pneumoniae, P. Mirabilis, C. 
freundii 
All β-lactams 
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Table 2: Currently available treatments for Gram-negative neonatal sepsis 
Drug 
Recommended IV dosage* 
CSF penetration Notes 
0-6 days 7-28 days 
Ampicillin  
30−60 mg/kg 
12 hourly 
30−60 mg/kg 
6−8 hourly 
Poor if meninges are not 
inflamed 
High doses can be administered because of low toxicity 
Amoxicillin 
50−100 mg/kg 
12 hourly 
50−100 mg/kg 
8 hourly 
Poor if meninges are not 
inflamed 
High doses can be administered because of low toxicity 
Piperacillin-
tazobactam 
90 mg/kg 
8 hourly 
90 mg/kg 
8 hourly 
Poor 
Active against most ESBL-producing Enterobacteriaceae 
but limited data in neonates 
Cefotaxime 
25−50 mg/kg 
12 hourly 
25−50 mg/kg 
6−8 hourly 
Adequate when 
meninges are inflamed 
High doses can be administered because of low toxicity 
Ceftazidime 
25−50 mg/kg 
once daily 
25−50 mg/kg 
8−12 hourly 
Adequate when 
meninges are inflamed 
High doses can be administered because of low toxicity 
Meropenem 
20-40 mg/kg 
12 hourly 
20-40 mg/kg 
8 hourly 
Adequate Active against ESBL-producing Enterobacteriaceae 
Gentamicin 
5 mg/kg  
36 hourly 
5 mg/kg  
24 hourly 
Poor TDM** required 
Ciprofloxacin 
10 mg/kg 
12 hourly 
10 mg/kg 
12 hourly 
Good Consider TDM in serious infections 
Colistin 
25,000 units/kg 
8 hourly 
25,000 units/kg 
8 hourly 
Inadequate 
TDM recommended. Active against Carbapenem-
resistant Enterobacteriaceae (CRE) 
Fosfomycin 
50 mg/kg 
12 hourly 
100 mg/kg 
12 hourly 
Good 
To use in combination to avoid development of 
resistance. 
Active against ESBL-producing Enterobacteriaceae and 
most CRE 
Tigecycline Insufficient data available Inadequate 
Active against ESBL-producing Enterobacteriaceae and 
CRE 
Modified from: Gray JW et al [40]. *Dosages according to those recommended in the British National 
Formulary for Children (BNFC) [41].  **TDM: Therapeutic Drug Monitoring 
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